Multiple sclerosis therapy: an update on recently finished trials (Q37001453)

17 August 2017

1 reference

title

Multiple sclerosis therapy: an update on recently finished trials (English)

1 reference

17 August 2017

0 references

3

Olaf Stüve

1 reference

17 August 2017

4

Bernd Kieseier

1 reference

17 August 2017

5

Heinz Wiendl

1 reference

17 August 2017

2

Sven G Meuth

1 reference

17 August 2017

Christoph Kleinschnitz

series ordinal

1

object named as

Christoph Kleinschnitz

1 reference

17 August 2017

publication date

15 November 2007

1 reference

17 August 2017

1 reference

17 August 2017

volume

254

1 reference

17 August 2017

issue

11

1 reference

17 August 2017

page(s)

1473-1490

1 reference

Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

An open label study of the effects of rituximab in neuromyelitis optica

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

Plasma exchange for severe optic neuritis: treatment of 10 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00415-007-0684-7

Hormonal treatment with sex steroids in women is associated with lower p105 serum concentrations

21 January 2018

1 reference

12 December 2020

T cell vaccination in multiple sclerosis relapsing-remitting nonresponders patients

1 reference

12 December 2020

Randomized study of once-weekly interferon beta-1la therapy in relapsing multiple sclerosis: three-year data from the OWIMS study

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders

1 reference

12 December 2020

Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients

1 reference

12 December 2020

Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study

1 reference

12 December 2020

Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones

1 reference

12 December 2020

The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.

1 reference

12 December 2020

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

12 December 2020

IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel

1 reference

12 December 2020

Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis

1 reference

12 December 2020

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Natalizumab effects on immune cell responses in multiple sclerosis

1 reference

12 December 2020

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

12 December 2020

First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients

1 reference

12 December 2020

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network

1 reference

12 December 2020

Treatment of active secondary progressive multiple sclerosis with treosulfan

1 reference

12 December 2020

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity

1 reference

12 December 2020

New directions in MS therapeutics: vehicles of hope

1 reference

12 December 2020

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

12 December 2020

A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.

1 reference

12 December 2020

Pregnancy and delivery of a healthy baby in autoimmune Lambert-Eaton myasthenic syndrome

1 reference

12 December 2020

Not every patient with multiple sclerosis should be treated at time of diagnosis

1 reference

12 December 2020

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

1 reference

12 December 2020

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

12 December 2020

Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS.

1 reference

12 December 2020

The many roles of chemokines and chemokine receptors in inflammation

1 reference

12 December 2020

Blockade of chemokine signaling in patients with multiple sclerosis

1 reference

12 December 2020

Needed in MS: evidence, not EVIDENCE

1 reference

12 December 2020

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.

1 reference

12 December 2020

Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies

1 reference

12 December 2020

Cyclophosphamide and plasma exchange in multiple sclerosis

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Early multiple sclerosis: to treat or not to treat?

1 reference

12 December 2020

Exploitation of the Vbeta8.2 T cell receptor in protection against experimental autoimmune encephalomyelitis using a live vaccinia virus vector

1 reference

12 December 2020

Plasma exchange for severe attacks of CNS demyelination: predictors of response

1 reference

12 December 2020

T-cell recognition of an immuno-dominant myelin basic protein epitope in multiple sclerosis

1 reference

12 December 2020

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

12 December 2020

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

1 reference

12 December 2020

HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis

1 reference

12 December 2020

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

1 reference

12 December 2020

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

12 December 2020

Use of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

12 December 2020

Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab

1 reference

12 December 2020

Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time

1 reference

12 December 2020

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin

1 reference

12 December 2020

Adherence to Medication

1 reference

12 December 2020

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study

1 reference

12 December 2020

1 reference

12 December 2020

Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85VVHFFKNIVTP96 in chronic progressive multiple sclerosis

1 reference

12 December 2020

Identification of autoantibodies associated with myelin damage in multiple sclerosis

1 reference

12 December 2020

When marketing and science intersect: do patients with MS benefit?

1 reference

12 December 2020

Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis

1 reference

12 December 2020

Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials

1 reference

12 December 2020

Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients

1 reference

12 December 2020

Suppressive vaccination with DNA encoding a variable region gene of the T-cell receptor prevents autoimmune encephalomyelitis and activates Th2 immunity

1 reference

12 December 2020

Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders

1 reference

12 December 2020

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis

1 reference

12 December 2020

Early treatment and dose optimisation BENEFIT and BEYOND.

1 reference

12 December 2020

Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Immunologic Mechanisms and Therapy in Multiple Sclerosis

1 reference

12 December 2020

Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients

1 reference

12 December 2020

The coming of age for antigen-specific therapy of multiple sclerosis

1 reference

12 December 2020

Other therapy options and future strategies for treating patients with multiple sclerosis

1 reference

12 December 2020

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

1 reference

12 December 2020

In vitro and in vivo T cell oligoclonality following chronic stimulation with staphylococcal superantigens

1 reference

12 December 2020

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?

1 reference

12 December 2020

1 reference

12 December 2020

Antigen-specific therapies in multiple sclerosis.

1 reference

12 December 2020

Immunotherapy of multiple sclerosis: the end of the beginning

1 reference

12 December 2020

Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial

1 reference

12 December 2020

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Statins as a newly recognized type of immunomodulator

1 reference

12 December 2020

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

12 December 2020

TCR peptide vaccination in multiple sclerosis: boosting a deficient natural regulatory network that may involve TCR-specific CD4+CD25+ Treg cells

1 reference

12 December 2020

Intravenous immunoglobulins for multiple sclerosis

1 reference

12 December 2020

Diagnostic criteria for multiple sclerosis

1 reference

12 December 2020

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment

1 reference

12 December 2020

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

1 reference

12 December 2020

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

1 reference

12 December 2020

Statins as immunomodulators: comparison with interferon-beta 1b in MS.

1 reference

12 December 2020

Human T-cell response to myelin basic protein peptide (83-99): extensive heterogeneity in antigen recognition, function, and phenotype

1 reference

12 December 2020

The ups and downs of multiple sclerosis therapeutics

1 reference

12 December 2020

Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes

1 reference

12 December 2020

Vaccination against autoimmune encephalomyelitis (EAE): Attenuated autoimmune T lymphocytes confer resistance to induction of active EAE but not to EAE mediated by the intact T lymphocyte line

1 reference

12 December 2020

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

12 December 2020

Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group

1 reference

12 December 2020

FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors

1 reference

12 December 2020

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

1 reference

12 December 2020

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis

1 reference

12 December 2020

Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines

1 reference

12 December 2020

MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)

1 reference

12 December 2020

An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis

1 reference

12 December 2020

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy

1 reference

12 December 2020

Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.

1 reference

12 December 2020

Suppression of experimentally induced autoimmune encephalomyelitis by cytolytic T-T cell interactions.

1 reference

12 December 2020

IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event

1 reference

12 December 2020

Chemokines and leukocyte traffic

1 reference

12 December 2020

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

1 reference

12 December 2020

Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation

1 reference

12 December 2020

Immune surveillance in multiple sclerosis patients treated with natalizumab.

1 reference

12 December 2020

A Longitudinal Study of Abnormalities on MRI and Disability from Multiple Sclerosis

1 reference

12 December 2020

Sirolimus: its discovery, biological properties, and mechanism of action

1 reference

12 December 2020

T cell vaccination induces T cell receptor Vβ-specific Qa-1-restricted regulatory CD8+T cells

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Natural history of primary progressive multiple sclerosis

1 reference

12 December 2020

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

1 reference

12 December 2020

Statins--a cure-all for the brain?

1 reference

12 December 2020

Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Drug Insight: using statins to treat neuroinflammatory disease

1 reference

12 December 2020

Primary progressive multiple sclerosis : current and future treatment options

1 reference

12 December 2020

1 reference

12 December 2020

The PROMiSe trial: baseline data review and progress report.

1 reference

12 December 2020

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

The immune modulator FTY720 targets sphingosine 1-phosphate receptors

1 reference

12 December 2020

Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange

1 reference

12 December 2020

Activity of hydrolytic enzymes in a case of subacute multiple sclerosis

1 reference

12 December 2020

Multiple sclerosis: in situ evidence for antibody- and complement-mediated demyelination

1 reference

12 December 2020

10.1007/S00415-007-0684-7

Identifiers

DOI

1 reference

release_wxufiixytzclvhmst4yvhklrju

17 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wxufiixytzclvhmst4yvhklrju

24 November 2022

mapped directly with Wikidata item

1 reference